CHARACTERIZATION OF CEFTAZIDIME RESISTANCE IN KLEBSIELLA PNEUMONIAE
肺炎克雷伯菌对头孢他啶耐药的特征
基本信息
- 批准号:6204152
- 负责人:
- 金额:$ 3.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-08-01 至 2000-07-31
- 项目状态:已结题
- 来源:
- 关键词:Klebsiella pneumoniae antibacterial agents beta lactamase cephalosporins drug resistance gene expression gene mutation genetic strain human tissue molecular cloning nosocomial infections nucleic acid hybridization nucleic acid sequence plasmids polymerase chain reaction pulsed field gel electrophoresis serology /serodiagnosis southern blotting
项目摘要
The introduction of highly stable Extended-Spectrum cephalosporins
at the beginning of the 1980's was quickly followed by the
emergence of several cephalosporin resistant Extended-Spectrum
beta-lactamases identified among clinical isolates of Klebsiella
pneumoniae. Homology studies of these enzymes suggested that
bacterial have adapted to the antibiotics by altering (amino acid
substitutions) existing plasmid-mediated beta-lactamases such to
expand their spectrum of activity. Subsequently, plasmids encoding
altered beta-lactamases were disseminated among gram-negative
clinical isolates. This resulted in increased beta-lactam antibiotic
resistance among clinical gram-negative bacteria. In this proposal,
an extensive investigation will be conducted to identify and
characterize novel beta-lactamases (derrived from amino acid
substitutions) identified in clinical isolates of Klebsiella
pneumoniae. Cephalosporin resistant Klebsiella pneumonia will be
identified by Kirby-Bauer disk diffusion susceptibility testing using
disk impregnated with cephalosporins (ceftazidime, cefotaxime, and
ceftriaxone). Isolates demonstrating Extended-Spectrum activity are
conjugated with susceptible E. Coli recipients to identify
transmissible beta-lactam resistance genes Transconjugates are
screened for the presence of TEM or SHV-type beta-lactamase
genes by polymerase chain reaction and Southern blot
hybridizations. Products obtained by PCR are sequenced to identify
novel mutations. Clones harboring mutations are cloned and
resequenced to confirm original findings. Data obtained from this
proposal will be instrumental in (1) the early detection of mutant
TEM and SHV-type beta-lactamases for proper treatment, (2)
maximizing the use of antibiotics currently available, (3)
establishing new forms of treatment, and (4) elucidating the trends
and mechanisms of drug resistance and transmission of TEM and
SHV-type beta-lactamases during nosocomial outbreaks. This
project will involve students in every aspect. Students will gain
invaluable knowledge and training in the fundamentals of DNA
manipulations, PCR technology, analysis of clinical samples, DNA
sequencing, data collection, and manuscript preparation. Training
obtained from this study will prepare students for doctoral studies in
cell, molecular, and microbiology.
高稳定性超广谱头孢菌素的引入
在20世纪80年代初,
出现几种头孢菌素耐药的超广谱抗生素
克雷伯菌临床分离株中鉴定的β-内酰胺酶
肺炎。 这些酶的同源性研究表明,
细菌通过改变(氨基酸)来适应抗生素
取代)现有的质粒介导的β-内酰胺酶,
扩大他们的活动范围。 随后,编码
改变的β-内酰胺酶在革兰阴性菌中传播,
临床分离株。 这导致β-内酰胺类抗生素
临床革兰氏阴性菌耐药性。 在这一提议中,
将进行广泛的调查,
表征新的β-内酰胺酶(衍生自氨基酸
在克雷伯氏菌临床分离株中鉴定的
肺炎。 头孢菌素耐药肺炎克雷伯菌将是
通过Kirby-Bauer纸片扩散敏感性试验鉴定,
用头孢菌素(头孢他啶、头孢噻肟和
头孢曲松)。 表现出超广谱活性的分离株为
与敏感的E.大肠杆菌感染者
可传播的β-内酰胺抗性基因
筛选是否存在TEM或SHV型β-内酰胺酶
PCR和Southern blot检测基因
杂交 通过PCR获得的产物被测序以鉴定
新的突变 克隆携带突变的克隆,
重新排序以确认原始结果。数据来源于此
该提案将有助于(1)早期发现突变体
TEM和SHV型β-内酰胺酶用于适当治疗,(2)
最大限度地使用目前可用的抗生素,(3)
建立新的治疗形式;(4)阐明趋势
以及TEM的耐药和传播机制,
医院内爆发的SHV型β-内酰胺酶 这
项目将涉及学生在各个方面。 学生将获得
DNA基础知识的宝贵知识和训练
操作,PCR技术,临床样本分析,DNA
测序、数据收集和手稿准备。 培训
从这项研究中获得的将为学生准备博士研究,
细胞、分子和微生物学
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James Edward Raynor其他文献
James Edward Raynor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James Edward Raynor', 18)}}的其他基金
U-RISE Program at Fayetteville State University
费耶特维尔州立大学 U-RISE 项目
- 批准号:
10599070 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
MBRS Research Initiative for Scientific Enhancement
MBRS 科学增强研究计划
- 批准号:
8508947 - 财政年份:2002
- 资助金额:
$ 3.95万 - 项目类别:
MBRS Research Initiative for Scientific Enhancement
MBRS 科学增强研究计划
- 批准号:
7761411 - 财政年份:2002
- 资助金额:
$ 3.95万 - 项目类别:
MBRS Research Initiative for Scientific Enhancement
MBRS 科学增强研究计划
- 批准号:
8248165 - 财政年份:2002
- 资助金额:
$ 3.95万 - 项目类别:
MBRS Research Initiative for Scientific Enhancement
MBRS 科学增强研究计划
- 批准号:
8855779 - 财政年份:2002
- 资助金额:
$ 3.95万 - 项目类别:
CHARACTERIZATION OF CEFTAZIDIME RESISTANCE IN KLEBSIELLA PNEUMONIAE
肺炎克雷伯菌对头孢他啶耐药的特征
- 批准号:
6338812 - 财政年份:2000
- 资助金额:
$ 3.95万 - 项目类别:
CHARACTERIZATION OF CEFTAZIDIME RESISTANCE IN KLEBSIELLA PNEUMONIAE
肺炎克雷伯菌对头孢他啶耐药的特征
- 批准号:
6107310 - 财政年份:1998
- 资助金额:
$ 3.95万 - 项目类别:
CHARACTERIZATION OF CEFTAZIDIME RESISTANCE IN KLEBSIELLA PNEUMONIAE
肺炎克雷伯菌对头孢他啶耐药的特征
- 批准号:
6240237 - 财政年份:1997
- 资助金额:
$ 3.95万 - 项目类别:
相似海外基金
Development of rapid detection method for drug-resistant bacteria in pulmonary MAC disease and search for new antibacterial agents
肺部MAC疾病耐药菌快速检测方法的建立及新型抗菌药物的寻找
- 批准号:
23K07930 - 财政年份:2023
- 资助金额:
$ 3.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of novel antibacterial agents using crystal structure-based drug screening
利用基于晶体结构的药物筛选开发新型抗菌剂
- 批准号:
23K07918 - 财政年份:2023
- 资助金额:
$ 3.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ATP Synthase as an emerging target for the pre-clinical development of broad-spectrum antibacterial agents against drug-resistant bacterial infections
ATP 合酶作为针对耐药细菌感染的广谱抗菌药物临床前开发的新兴靶标
- 批准号:
472342 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
Operating Grants
Clinical application of a rapid assay for antibacterial susceptibility test of beta-lactams and carbapenems antibacterial agents using MALDI-TOF MS
MALDI-TOF MS快速测定β-内酰胺类和碳青霉烯类抗菌药物药敏试验的临床应用
- 批准号:
22K07406 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Tailored and uniform fibre-like micelles as antibacterial agents.
定制且均匀的纤维状胶束作为抗菌剂。
- 批准号:
569719-2022 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
Postgraduate Scholarships - Doctoral
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体
- 批准号:
531450-2018 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
Collaborative Research and Development Grants
Novel silver nanoparticles as antibacterial agents
作为抗菌剂的新型银纳米颗粒
- 批准号:
521908-2018 - 财政年份:2021
- 资助金额:
$ 3.95万 - 项目类别:
Collaborative Research and Development Grants
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体
- 批准号:
531450-2018 - 财政年份:2021
- 资助金额:
$ 3.95万 - 项目类别:
Collaborative Research and Development Grants
Novel silver nanoparticles as antibacterial agents
作为抗菌剂的新型银纳米颗粒
- 批准号:
521908-2018 - 财政年份:2020
- 资助金额:
$ 3.95万 - 项目类别:
Collaborative Research and Development Grants
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents.
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体。
- 批准号:
531450-2018 - 财政年份:2020
- 资助金额:
$ 3.95万 - 项目类别:
Collaborative Research and Development Grants














{{item.name}}会员




